- Thinly traded nano cap ArQule (NASDAQ:ARQL) comes up empty again with lead product candidate tivantinib. A Phase 3 clinical trial, JET-HCC, in 190 Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma (HCC) previously treated with sorafenib (Bayer's Nexavar) failed to beat placebo as measured by progression-free survival (PFS).
- Detailed results will be presented at an upcoming scientific meeting.
- In February, tivantinib failed to beat best supportive care in a late-stage HCC study.
- Shares are down 22% premarket on average volume.
- Previously: ArQule's lead product candidate tivantinib flunks late-stage liver cancer study; shares down 16% (Feb. 17)